Not recruiting
Gaucher's disease type I
Not recruitingInvestigationalNo placebo
Study on the Long-term Safety of FLT201 for Patients with Gaucher Disease Type 1
InvestigationalNo placebo
- Disease:Gaucher's disease type I
- Substances:Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant
- Sponsor:Spur Therapeutics Limited
